General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Abcam plc in Offering on Nasdaq

October 22, 2020
Cross-border capital markets team represented the global life sciences company in the dual-listing.

Abcam plc (Abcam), a global leader in the supply of life science research tools, has announced the pricing of its offering of 8,945,218 American Depositary Shares (ADSs), representing an aggregate of 8,945,218 ordinary shares, at a price of US$17.50 per ADS, for aggregate proceeds of approximately US$156.5 million, before deducting underwriting discounts and commissions. Each ADS offered represents one ordinary share of Abcam. In addition, Abcam has granted the underwriters a 30-day option to purchase up to an additional 1,341,782 ADSs on the same terms and conditions. Abcam's ordinary shares are admitted to trading on the AIM market of the London Stock Exchange under the symbol "ABC." Abcam’s ADSs are expected to begin trading on Nasdaq on October 22, 2020 under the ticker symbol “ABCM.” The closing of the offering is expected to occur on October 26, 2020, subject to customary closing conditions.

Latham & Watkins LLP represented Abcam in the offering with a capital markets team led by New York partners Ian Schuman and Nathan Ajiashvili and London partner Robbie McLaren, with London associates Jennifer Gascoyne, Anna Ngo, Sarah Youssefi, Jackie Yonover, and Frederick Gardner.